Disease · MONDO_0011996
Comparisons in its trials87
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 87
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Imatinib (STI571) vs IFN-a + Ara-C: Number of Participants With Serious Adverse Events as a Measure of Safety (First-line Treatment) | 226 of 551 | 163 of 533 | 1,084 | NCT00333840 | Trial comparisons |
| Dasatinib 140 mg QD vs Dasatinib 70 mg BID: serious adverse events | 228 of 304 | 236 of 305 | 609 | NCT00123487 | Trial comparisons |
| Bosutinib vs Imatinib: deaths from any cause | 14 of 268 | 14 of 268 | 536 | NCT02130557 | Trial comparisons |
| Bosutinib vs Imatinib: Number of Participants With Adverse Events (AEs) Leading to Study Drug Discontinuation | 68 of 268 | 38 of 265 | 533 | NCT02130557 | Trial comparisons |
| Bosutinib vs Imatinib: serious adverse events | 98 of 268 | 68 of 265 | 533 | NCT02130557 | Trial comparisons |
| Bosutinib vs Imatinib: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | 16 of 266 | 13 of 262 | 528 | NCT02130557 | Trial comparisons |
| Bosutinib vs Imatinib: Number of Participants With Vital Signs Abnormalities | 107 of 262 | 109 of 263 | 525 | NCT02130557 | Trial comparisons |
| Dasatinib vs Imatinib: Number of Participants With Best Confirmed Complete Cytogenetic Response (cCCyR) Within 12 Months | 204 of 259 | 177 of 260 | 519 | NCT00481247 | Trial comparisons |
| Dasatinib vs Imatinib: serious adverse events | 90 of 258 | 70 of 258 | 516 | NCT00481247 | Trial comparisons |
| Bosutinib vs Imatinib: serious adverse events | 90 of 248 | 57 of 251 | 499 | NCT00574873 | Trial comparisons |
| Imatinib 400mg vs Imatinib 800mg: serious adverse events | 42 of 157 | 121 of 316 | 473 | NCT00124748 | Trial comparisons |
| CML-CP With Prior Imatinib Only vs CML-AP With Prior Imatinib Only: Participants With (MMR) Major Molecular Response (Phase II) | 106 of 299 | 18 of 122 | 421 | NCT00109707 | Trial comparisons |
| Asciminib (All Asciminib ) vs Investigator Selected TKI (All Comparators): Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI | 136 of 201 | 100 of 204 | 405 | NCT04971226 | Trial comparisons |
| Intolerant vs Resistant: serious adverse events | 48 of 99 | 146 of 288 | 387 | NCT00101660 | Trial comparisons |
| Imatinib to IFN-a + Ara-C vs IFN-a + Ara-C to Imatinib: Number of Participants With Serious Adverse Events as a Measure of Safety (Second-line Treatment) | 2 of 14 | 160 of 363 | 377 | NCT00333840 | Trial comparisons |
| INTRON A, 5 MIU/m^2 Daily vs PEG-Intron, 6.0 mcg/kg Weekly: deaths from any cause | 15 of 173 | 17 of 171 | 344 | NCT03547154 | Trial comparisons |
| INTRON A, 5 MIU/m^2 Daily vs PEG-Intron, 6.0 mcg/kg Weekly: serious adverse events | 62 of 173 | 74 of 171 | 344 | NCT03547154 | Trial comparisons |
| Ponatinib 45 mg vs Imatinib 400 mg: serious adverse events | 49 of 154 | 13 of 152 | 306 | NCT01650805 | Trial comparisons |
| Imatinib 400 mg qd vs Nilotinib 300 mg Bid: serious adverse events | 13 of 132 | 11 of 133 | 265 | NCT01275196 | Trial comparisons |
| Asciminib vs Bosutinib: Number of Participants With Major Molecular Response (MMR) Rate at 24 Weeks | 40 of 157 | 10 of 76 | 233 | NCT03106779 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011996/comparisons